DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Bladder Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Cambridge University NHS FT, Cambridge, United Kingdom
Contact: Study coordinator (Will Ince, MBBS, MRCGP, MRCP, FRCR)Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Contact: Study coordinator (Deborah Enting, MSc MBBS MRCP PGDip CCT)Royal Free London NHS FT, London, United Kingdom
Contact: Study coordinator (Antonio Rullan, MBBS, MSc, PhD)The Royal Marsden NHS Foundation Trust, London, United Kingdom
Contact: Study coordinator (Vincent Khoo, MBBS FRACR FRCR MD (Res)University College London Hospital NHS Foundation Trust, London, United Kingdom
Contact: Study coordinator (Mark Linch BSc (Hons) MBChB FRCP PhD)The Christie NHS Foundation Trust, Manchester, United Kingdom
Contact: Study coordinator (Yee Pei Song, MB BCh BAO, MRCP, FRCR)University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Contact: Study coordinator (Simon Crabb, BSc MBBS MRCP PhD CCT)
Study leads
Mark Linch
Principal Investigator
University College London Hospitals